[{"id":"0b154df6-4ebb-42ce-a9c2-2bdabd8ac5fb","acronym":"","url":"https://clinicaltrials.gov/study/NCT06115135","created_at":"2023-11-02T15:13:03.515Z","updated_at":"2024-07-02T16:35:22.451Z","phase":"Phase 2","brief_title":"A Study of Venetoclax in Combination With Isatuximab and Dexamethasone for Relapsed/Refractory Multiple Myeloma","source_id_and_acronym":"NCT06115135","lead_sponsor":"Oncotherapeutics","biomarkers":" BCL2 • TNFA","pipe":" | ","alterations":" Chr t(11;14)","tags":["BCL2 • TNFA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr t(11;14)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • carfilzomib • Sarclisa (isatuximab-irfc) • dexamethasone injection"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 39","initiation":"Initiation: 03/01/2024","start_date":" 03/01/2024","primary_txt":" Primary completion: 03/31/2026","primary_completion_date":" 03/31/2026","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2024-01-24"},{"id":"13d940c3-64f2-4c13-a92c-5be14974fb4b","acronym":"","url":"https://clinicaltrials.gov/study/NCT03499808","created_at":"2021-01-18T17:13:44.637Z","updated_at":"2024-07-02T16:35:24.603Z","phase":"Phase 2","brief_title":"S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis","source_id_and_acronym":"NCT03499808","lead_sponsor":"SWOG Cancer Research Network","biomarkers":" NPPB","pipe":" | ","alterations":" Chr t(11;14) • Chr t(4;14) • Chr t(14;16)","tags":["NPPB"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr t(11;14) • Chr t(4;14) • Chr t(14;16)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Sarclisa (isatuximab-irfc)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 43","initiation":"Initiation: 06/06/2018","start_date":" 06/06/2018","primary_txt":" Primary completion: 12/31/2023","primary_completion_date":" 12/31/2023","study_txt":" Completion: 07/31/2025","study_completion_date":" 07/31/2025","last_update_posted":"2024-01-04"},{"id":"f98339f3-8da6-4706-ab29-7a338e6db7fa","acronym":"TTI-622-01","url":"https://clinicaltrials.gov/study/NCT03530683","created_at":"2021-07-15T16:53:02.099Z","updated_at":"2024-07-02T16:35:25.423Z","phase":"Phase 1","brief_title":"A Clinical Trial to Learn About the Study Medicine Called Maplirpacept (PF-07901801), Alone and When Used in Combination With Other Medicines to Treat Participants With Advanced Hematological Malignancies, Including Lymphoma, Leukemia and Multiple Myeloma","source_id_and_acronym":"NCT03530683 - TTI-622-01","lead_sponsor":"Pfizer","biomarkers":" TP53","pipe":" | ","alterations":" TP53 mutation • TP53 wild-type","tags":["TP53"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • TP53 wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Rituxan (rituximab) • azacitidine • carfilzomib • dexamethasone • Sarclisa (isatuximab-irfc) • dexamethasone injection • maplirpacept (TTI-622)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 177","initiation":"Initiation: 06/07/2018","start_date":" 06/07/2018","primary_txt":" Primary completion: 09/11/2024","primary_completion_date":" 09/11/2024","study_txt":" Completion: 09/11/2024","study_completion_date":" 09/11/2024","last_update_posted":"2023-12-22"},{"id":"5fbd1607-3a0e-4647-9158-4e60480d4470","acronym":"ISABEL","url":"https://clinicaltrials.gov/study/NCT04965155","created_at":"2021-07-16T13:53:20.587Z","updated_at":"2024-07-02T16:35:25.810Z","phase":"Phase 2","brief_title":"A Trial for Relapsed Multiple Myeloma Patients (Isatuximab-dexamethasone)","source_id_and_acronym":"NCT04965155 - ISABEL","lead_sponsor":"EMN Research Italy","biomarkers":" CD34","pipe":"","alterations":" ","tags":["CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carfilzomib • dexamethasone • Sarclisa (isatuximab-irfc) • melphalan"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 03/21/2021","start_date":" 03/21/2021","primary_txt":" Primary completion: 11/28/2023","primary_completion_date":" 11/28/2023","study_txt":" Completion: 03/31/2027","study_completion_date":" 03/31/2027","last_update_posted":"2023-12-19"},{"id":"43e62691-00c7-4f18-90a0-335ab0e5f78a","acronym":"","url":"https://clinicaltrials.gov/study/NCT01084252","created_at":"2021-01-18T04:16:33.894Z","updated_at":"2024-07-02T16:35:34.498Z","phase":"Phase 1/2","brief_title":"Phase 1/2 Dose Escalation and Efficacy Study of Anti-CD38 Monoclonal Antibody in Patients With Selected CD38+ Hematological Malignancies","source_id_and_acronym":"NCT01084252","lead_sponsor":"Sanofi","biomarkers":" IFNG • IL6 • TNFA • CRP","pipe":"","alterations":" ","tags":["IFNG • IL6 • TNFA • CRP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dexamethasone • Sarclisa (isatuximab-irfc)"],"overall_status":"Completed","enrollment":" Enrollment 351","initiation":"Initiation: 06/10/2010","start_date":" 06/10/2010","primary_txt":" Primary completion: 12/21/2018","primary_completion_date":" 12/21/2018","study_txt":" Completion: 07/13/2023","study_completion_date":" 07/13/2023","last_update_posted":"2023-10-06"},{"id":"d887730a-1b8c-4c70-a806-caec6a1580f0","acronym":"ICING","url":"https://clinicaltrials.gov/study/NCT04763616","created_at":"2021-02-21T13:52:33.511Z","updated_at":"2024-07-02T16:36:24.044Z","phase":"Phase 2","brief_title":"Study of Isatuximab and Cemiplimab in Relapsed or Refractory Natural Killer/T-cell Lymphoid Malignancy","source_id_and_acronym":"NCT04763616 - ICING","lead_sponsor":"Won Seog Kim","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Libtayo (cemiplimab-rwlc) • Sarclisa (isatuximab-irfc)"],"overall_status":"Recruiting","enrollment":" Enrollment 37","initiation":"Initiation: 06/25/2021","start_date":" 06/25/2021","primary_txt":" Primary completion: 04/30/2023","primary_completion_date":" 04/30/2023","study_txt":" Completion: 04/30/2026","study_completion_date":" 04/30/2026","last_update_posted":"2021-09-24"}]